Echelon Biosciences

About Echelon Biosciences

Echelon Biosciences Incorporated (EBI) was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. Initially, EBI was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, with the aim to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.

From 1997 through 2004, EBI primarily used government grants and product sales revenues to fund its research efforts. In early 2005, EBI was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP anti-infectives, PI3-Kinase small molecule program, catalog business, and scientific expertise. In late 2007, Frontier Scientific Incorporated (FSI) based in Logan, Utah purchased EBI. Specializing in porphyrin and boron chemistry, FSI opened the doors for expanded research.

Since 1997, EBI has retained its commitment to developing novel assays and reagents for lipid research and beyond. At EBI’s core is the desire to innovate, thus pushing medicinal research to new limits. We look forward to providing scientists around the world with the tools they need to cure human disease states for years to come and we welcome any suggestions about how we can better do so.


Social Media Marketing Intern

January 2023 - May 2023 Salt Lake City, UT
“Super friendly team. Everyone got to know me. I was given a ton of freedom to work on things I felt were important and my opinions were respected and valued.”
See All